We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Udg Healthcare Public Limited Company | UDG | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 1,079.00 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 1,079.00 | 1,079.00 |
| Top Posts |
|---|
Posted at 30/5/2021 09:17 by carcosa FT:M&G Investments, the £367bn asset manager, has blasted plans to sell London-listed UDG Healthcare to buyout firm Clayton, Dubilier & Rice, the latest in a series of criticisms of private equity deals by big fund managers. Shareholders are due to vote in June on the £2.8bn all-cash offer to sell UDG, which provides clinical, commercial, communication and packaging services for the healthcare industry. But London-based M&G, which is a top-five shareholder in UDG according to data provider CapitalIQ, said the bid “fails to offer fair value to ordinary shareholders, including the customers on whose behalf we invest”. Allianz Global Investors, UDG’s largest shareholder, has also criticised the deal. Earlier this month, Elliott Investment Management, the activist investor, said it had taken a stake in the Dublin-headquartered company. The criticism by M&G and AllianzGI comes at a time of growing concern in the UK that listed companies are being sold off too cheaply to private equity firms. While fund managers rarely make public statements on companies, some have decided to speak out about deals involving private equity in recent weeks, including Schroders, which criticised transport operator FirstGroup’s planned £3.3bn sale of its US business to Swedish buyout group EQT. Private equity groups, many of which have raised their largest-ever funds, are targeting the UK stock market with the aim of capitalising on lower valuations in the wake of Brexit and the pandemic. Thirteen private equity buyouts of UK-listed companies have been announced since the beginning of 2021, the highest year-to-date figure since 2006, according to figures from Refinitiv. Just two were announced during the same period in 2019. Rory Alexander, a fund manager at M&G, said he was concerned that CD&R would benefit from the UDG deal at the expense of ordinary investors. “The $3.7bn offer does not reflect the potential long term value creation of UDG’s organic growth story, opportunity for strategic acquisitions, consistent cash generation and fortress balance sheet,” he said. “The material mismatch between the offer price and our opinion of UDG’s true value represents upside transferred away from ordinary shareholders towards the private equity bidder.” UDG declined to comment. But when the deal was announced on May 12, UDG chair Shane Cooke, said it was an “attractive offer”. He added that it “secures the delivery of future value for shareholders in cash today. The offer reflects the quality, strength and long term performance of UDG’s businesses and its future growth potential”. CD&R declined to comment. AllianzGI, which owns 8.6 per cent of UDG’s shares, said earlier this month that the price did “not adequately compensate existing shareholders”, adding that it was the duty of the board to “obtain a fair value for shareholders”. “AllianzGI firmly believes that the offer is opportunistic and significantly undervalues UDG and its prospects and is not in the best interests of shareholders. Consequently, based on available information, AllianzGI is minded not to accept the current offer despite it being recommended to shareholders by the Board of UDG,” it added. |
Posted at 03/6/2020 13:33 by 3rd eye UDG Healthcare..........Interesting to see the forward forecast for the company. As per the majority of stock it will take a (very small) hit for 30/09/2020 but then in 2021 bounces back with vengeance, with a 16% rise in EPS which would put it on a p/e of 17 and a PEG of 1........in other words a (late) Jim Slater ZULU principle stock. SEE forward forecasts below. FORECAST year Ending Revenue (€m) Pre-tax(€m) EPS P/E PEG EPS Growth Div Yield 2020-09-30 1,005.48 102.04 36.88p 20.1 -4.8 -4% 11.18p 1.5% 2021-09-30 1,087.20 122.83 42.91p 17.1 1.0 16% 15.01p 2.0% CHART SP as moved above the 200 day moving average a bullish sign. In a lovely uptrend. |
Posted at 22/5/2020 10:29 by 3rd eye UDG Broker Forecasts..........Latest broker views Date Broker Recomm. Current Price Price when issued Old price New price 22 May 20 Berenberg Buy 692.50 694.00 740.00 880.00 19 May 20 Liberum Capital Buy 692.50 623.50 900.00 - 19 May 20 Peel Hunt Buy 692.50 623.50 1,165.00 |
Posted at 22/5/2020 10:12 by 3rd eye UDG Healthcare UDG.. worth a bob or two investment.UDG valuation is ‘compelling Healthcare packaging company UDG Healthcare (UDG) is trading on a ‘compelling valuation’ for a market leader, says Berenberg. Analyst Eoghan Read retained his ‘buy’ recommendation and increased his target price from 740p to 880p. The shares rose 1.6% to 692.5p yesterday. First-half results from the group beat Read’s forecasts by 6% and he said while it had not been immune from the impact of Covid-19, his ‘confidence in the equity story’ had increased thanks to positive momentum, operating resilience, and the ‘long-term structural drivers evident in the market’. ‘UDG remains one of our top picks in our UK mid-cap business services coverage,’ he said. ‘Trading on a 20% discount to long-term average and US peers, we think it now presents a compelling valuation opportunity for a structurally growing and market-leading operator.’ ==================== Lovely uptrend channel on the chart. If it breaks through the ceiling of the channel, next share price target mid term is 730p approx. P/E 19 for 2021, cheap considering the Boom in Bios and health at the moment. |
Posted at 31/1/2020 16:20 by brain smiley UDG organises meeting and events for the drugs industry in China.Will they have to be cancelledand how much profit do they make from them ? |
Posted at 19/2/2019 14:55 by brain smiley Very poor performer.ShorttrackWouldn't be surprised to see more director buying. |
Posted at 11/1/2019 09:23 by soundbuy Ex-divi vs record date............ |
Posted at 11/1/2019 09:11 by mfhmfh From the Preliminary Results from 27.11.18:'Subject to shareholder approval at the Company's Annual General Meeting, the proposed final dividend of 11.75 $ cent per share will be paid on 4 February 2019 to ordinary shareholders on the Company's register at 5.00 p.m. on 11 January 2019.' |
Posted at 11/1/2019 08:48 by soundbuy Ex-divi 10th ? |
Posted at 11/1/2019 08:45 by thedoghouser Erm that’s negligible news - it’s fine ex dividend today - nothing more sinister |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
